California renews LifeStem's biologics license

3 December 2007

CalbaTech, a US life sciences company focused on the collection and banking of adult stem cells for possible future uses, says that the California Department of Public Health has renewed LifeStem's biologics license. LifeStem is the wholly-owned subsidiary of CalbaTech in the business of collecting adult stem cells.

"Management has worked diligently to make sure that LifeStem's biologics license was renewed. As such, LifeStem's protocols and procedures have met the standards as set by the State of California. LifeStem has recently completed training at the state-of-the-art Youthtopia Med Spa in a suburb of Atlanta, and Youthtopia is covered under our biologics license," said James DeOlden, chief executive of CalbaTech.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight